LIFECARE AS NOK 0,40 Logo
NO0010591191
A2DUKY
LIFE.OL

LIFECARE AS NOK 0,40

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Lifecare reduces operating loss in Q2 2026 and secures financing until Q2 2027

    Lifecare reports an operating loss of NOK 10.6m for Q2 2026 versus NOK 22m in the prior year and improved liquidity of NOK 37m. Revenue remained minimal at NOK 250,000, coming from a government grant; net profit of NOK 4.5m resulted from revaluations and the deconsolidation of the German subsidiary. Management plans to relocate and build a controlled production facility in Bergen as a prerequisite for the CE submission; financial runway is expected to last until Q2 2027, but a CE timeline in 2027 remains uncertain. » More on de.investing.com

Financials

In the last quarter, LIFECARE AS NOK 0,40 had revenue of €34.67K and net profit of -€1.12M
(EUR) September 2026
YoY
Revenue 34.67K 24.30%
Gross profit 0 -
Net profit -1.12M 79.67%
EBITDA -1.06M 80.28%

Fundamentals

Metric Value
Market capitalization
€14.24M
Number of shares
430.36M
52-week high/low
€0.55 - €0.0255
Dividends No
Beta
-0.43
P/E ratio
-0.55
PEG ratio
0.00
P/B ratio
2.89
P/S ratio
99.43

Company profile

Lifecare AS engages in the research and development of medical sensors for health monitoring in Norway. It develops Sencell, a micro sensor for monitoring glucose levels in patients with diabetes. The company was founded in 2006 and is headquartered in Bergen, Norway.

Name
LIFECARE AS NOK 0,40
CEO
Joacim Holter
Headquarters Bergen, hl
Norway
Website
IPO
07/11/2018
Employees 22

Ticker symbols

Exchange Symbol
Osl
LIFE.OL
Frankfurt
LFC.F
Düsseldorf
LFC.DU
München
LFC.MU
🍪

Parqet  uses cookies. Learn more